Literature DB >> 27677760

Serum IgG levels and mortality in patients with severe sepsis and septic shock : The SBITS data.

S Dietz1, C Lautenschläger2, U Müller-Werdan3, G Pilz4, P Fraunberger5, M Päsler6, H Ebelt7, A K Walli8, K Werdan9, S Nuding10.   

Abstract

BACKGROUND: The role of intravenous immune globulin (Ig) therapy in patients with severe sepsis and septic shock is discussed controversially. Low initial IgG levels could help to identify those patients who might benefit from an adjunctive Ig treatment.
OBJECTIVES: To investigate the effect of initial serum IgG levels on 28-day mortality in patients with severe sepsis and septic shock.
MATERIALS AND METHODS: In this retrospective analysis of the SBITS trial data, 543 patients were allocated to four groups (quartiles) depending on their initial serum IgG levels (1: IgG ≤ 6.1 g/l; 2: IgG 6.2-8.4 g/l; 3: IgG 8.5-11.9 g/l; 4: IgG > 11.9 g/l). The third quartile was taken as the reference quartile. For the applied logistic regression model clinically relevant confounders were defined and integrated into further risk-adjusted calculations.
RESULTS: Patients with the lowest IgG levels had a mortality rate similar to those patients with initial IgG levels in the second and third quartile, representing the physiological IgG range in healthy people. Surprisingly, patients with the highest IgG levels even showed a significantly higher mortality in a risk-adjusted calculation compared to the reference quartile (OR 1.69, CI 1.01-2.81, p = 0.05). Subgroup analyses revealed that initial IgG levels were of no prognostic value in patients presenting with vasopressor-dependent septic shock on admission as well as in patients with either gram-positive or gram-negative sepsis.
CONCLUSIONS: Initially low IgG levels do not discriminate between survival and nonsurvival in patients with severe sepsis and septic shock. Therefore, low IgG cannot help to identify those patients who might benefit from an adjunctive IgG sepsis therapy. Whether a high initial IgG serum level is an independent mortality risk factor needs to be investigated prospectively.

Entities:  

Keywords:  Immunoglobulins; SBITS trial; Sepsis; Septic shock; Serum IgG level

Mesh:

Substances:

Year:  2016        PMID: 27677760     DOI: 10.1007/s00063-016-0220-6

Source DB:  PubMed          Journal:  Med Klin Intensivmed Notfmed        ISSN: 2193-6218            Impact factor:   0.840


  30 in total

1.  Human intravenous immunoglobulin modulates monokine production in vitro.

Authors:  J P Andersson; U G Andersson
Journal:  Immunology       Date:  1990-11       Impact factor: 7.397

Review 2.  The role of complement in inflammatory diseases from behind the scenes into the spotlight.

Authors:  Maciej M Markiewski; John D Lambris
Journal:  Am J Pathol       Date:  2007-07-19       Impact factor: 4.307

Review 3.  Complement evasion by human pathogens.

Authors:  John D Lambris; Daniel Ricklin; Brian V Geisbrecht
Journal:  Nat Rev Microbiol       Date:  2008-02       Impact factor: 60.633

4.  Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012.

Authors:  Kirsi-Maija Kaukonen; Michael Bailey; Satoshi Suzuki; David Pilcher; Rinaldo Bellomo
Journal:  JAMA       Date:  2014-04-02       Impact factor: 56.272

5.  A randomized trial of protocol-based care for early septic shock.

Authors:  Donald M Yealy; John A Kellum; David T Huang; Amber E Barnato; Lisa A Weissfeld; Francis Pike; Thomas Terndrup; Henry E Wang; Peter C Hou; Frank LoVecchio; Michael R Filbin; Nathan I Shapiro; Derek C Angus
Journal:  N Engl J Med       Date:  2014-03-18       Impact factor: 91.245

6.  [Prevention and follow-up care of sepsis. 1st revision of S2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V., DSG) and the German Interdisciplinary Association of Intensive Care and Emergency Medicine (Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin, DIVI)].

Authors:  F M Brunkhorst; P Gastmeier; W Kern; W Krüger; K Mayer; A Weimann; T Welte; C Putensen; K Werdan; K Reinhart
Journal:  Internist (Berl)       Date:  2010-07       Impact factor: 0.743

Review 7.  Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock.

Authors:  Marissa M Alejandria; Mary Ann D Lansang; Leonila F Dans; Jacinto Blas Mantaring
Journal:  Cochrane Database Syst Rev       Date:  2013-09-16

8.  Gamma-globulin levels in patients with community-acquired septic shock.

Authors:  Fabio Silvio Taccone; Patrick Stordeur; Daniel De Backer; Jacques Creteur; Jean-Louis Vincent
Journal:  Shock       Date:  2009-10       Impact factor: 3.454

9.  Immunoglobulin G treatment of postcardiac surgery patients with score-identified severe systemic inflammatory response syndrome--the ESSICS study.

Authors:  Karl Werdan; Günter Pilz; Ursula Müller-Werdan; Monika Maas Enriquez; Dierk V Schmitt; Friedrich-Wilhelm Mohr; Gertraud Neeser; Friedrich Schöndube; Hans-Joachim Schäfers; Axel Haverich; Peter Fraunberger; Jan Andersson; Eckart Kreuzer; Lambert G Thijs
Journal:  Crit Care Med       Date:  2008-03       Impact factor: 7.598

10.  Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation.

Authors:  R Rieben; A Roos; Y Muizert; C Tinguely; A F Gerritsen; M R Daha
Journal:  Blood       Date:  1999-02-01       Impact factor: 22.113

View more
  7 in total

Review 1.  Advances in Immune Monitoring Approaches for Sepsis-Induced Immunosuppression.

Authors:  Ren-Qi Yao; Chao Ren; Li-Yu Zheng; Zhao-Fan Xia; Yong-Ming Yao
Journal:  Front Immunol       Date:  2022-05-10       Impact factor: 8.786

2.  Comparison of Total Immunoglobulin G in Ante- and Postmortem Blood Samples from Tissue Donors.

Authors:  Gudrun Larscheid; Tino Schulz; Hermann Herbst; Tina Trögel; Sascha Eulert; Axel Pruß; Jan Schroeter
Journal:  Transfus Med Hemother       Date:  2021-01-05       Impact factor: 3.747

Review 3.  The Role of Adjunctive Therapies in Septic Shock by Gram Negative MDR/XDR Infections.

Authors:  Stefano Busani; Erika Roat; Giulia Serafini; Elena Mantovani; Emanuela Biagioni; Massimo Girardis
Journal:  Can J Infect Dis Med Microbiol       Date:  2017-07-09       Impact factor: 2.471

4.  The protective association of endogenous immunoglobulins against sepsis mortality is restricted to patients with moderate organ failure.

Authors:  Ignacio Martin-Loeches; Arturo Muriel-Bombín; Ricard Ferrer; Antonio Artigas; Jordi Sole-Violan; Leonardo Lorente; David Andaluz-Ojeda; Adriele Prina-Mello; Ruben Herrán-Monge; Borja Suberviola; Ana Rodriguez-Fernandez; Pedro Merino; Ana M Loza; Pablo Garcia-Olivares; Eduardo Anton; Eduardo Tamayo; Wysali Trapiello; Jesús Blanco; Jesús F Bermejo-Martin
Journal:  Ann Intensive Care       Date:  2017-04-20       Impact factor: 6.925

5.  Intravenous immunoglobulin fails to improve ARDS in patients undergoing ECMO therapy.

Authors:  Stefanie Prohaska; Andrea Schirner; Albina Bashota; Andreas Körner; Gunnar Blumenstock; Helene A Haeberle
Journal:  J Intensive Care       Date:  2018-02-26

6.  Risk factor analysis and nomogram for predicting in-hospital mortality in ICU patients with sepsis and lung infection.

Authors:  Yinlong Ren; Luming Zhang; Fengshuo Xu; Didi Han; Shuai Zheng; Feng Zhang; Longzhu Li; Zichen Wang; Jun Lyu; Haiyan Yin
Journal:  BMC Pulm Med       Date:  2022-01-07       Impact factor: 3.317

Review 7.  Sepsis-induced immunosuppression: mechanisms, diagnosis and current treatment options.

Authors:  Di Liu; Si-Yuan Huang; Jian-Hui Sun; Hua-Cai Zhang; Qing-Li Cai; Chu Gao; Li Li; Ju Cao; Fang Xu; Yong Zhou; Cha-Xiang Guan; Sheng-Wei Jin; Jin Deng; Xiang-Ming Fang; Jian-Xin Jiang; Ling Zeng
Journal:  Mil Med Res       Date:  2022-10-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.